Karyopharm Therapeutics (NASDAQ:KPTI) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report report published on Friday, Benzinga reports. They currently have a $7.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird dropped their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $0.90 on Friday. Karyopharm Therapeutics has a 1 year low of $0.62 and a 1 year high of $1.95. The company has a market capitalization of $112.61 million, a P/E ratio of -0.77 and a beta of 0.16. The company has a 50 day simple moving average of $0.80 and a 200-day simple moving average of $0.92.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million during the quarter, compared to analysts’ expectations of $36.07 million. As a group, research analysts expect that Karyopharm Therapeutics will post -0.95 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KPTI. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics in the second quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth $143,000. Acadian Asset Management LLC acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth $167,000. Exchange Traded Concepts LLC increased its holdings in Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares during the period. Finally, Ikarian Capital LLC raised its position in Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).